Status:
UNKNOWN
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Lead Sponsor:
Medical University of Vienna
Conditions:
Lymphoma, Mantle-Cell
Eligibility:
All Genders
19-75 years
Phase:
PHASE2
Brief Summary
Mantle cell lymphoma (MCL) remains difficult to treat by standard treatment approaches. Novel drugs have shown promising results in early clinical evaluations. In the current trial, we investigate a c...
Detailed Description
Description of the treatment regimen: Bortezomib: 1.3 mg/m2 as i.v. bolus injection, given on days 1, 4, 8, and 11 of each treatment cycle; Rituximab: 375 mg/m2 infusion, day 1 of each cycle; Dexameth...
Eligibility Criteria
Inclusion
- mantle cell lymphoma at stage II - IV, previously treated with at least one line of prior therapy (CHOP or CHOP-like), measurable disease, age 19 - 75 years, adequate cardiac, liver and renal function tests, patient's written informed consent
Exclusion
- second malignancy, evidence for CNS involvement, clinically significant peripheral neuropathy (grade II or higher), HIV positivity, pregnancy
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00261612
Start Date
January 1 2005
End Date
January 1 2007
Last Update
October 18 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology
Vienna, Austria